Literature DB >> 3136999

A modified host protein model of scrapie.

D C Bolton1, P E Bendheim.   

Abstract

The scrapie agent is still not completely characterized biochemically and ultrastructurally, but its requirement for a functional protein has been established. Purification of the scrapie agent by methods using digestion with proteinase K yields a glycoprotein with an apparent mass of 27-30 kDa (PrP 27-30). In contrast, a 33-37 kDa glycoprotein, called Sp33-37, is the major protein component isolated from scrapie-affected brain when protease digestion is not used. Sp33-37 is the product of a normal host gene and is a larger form of PrP 27-30. We propose a model in which Sp33-37, a modified host protein, is the critical component of the scrapie agent; a non-host nucleic acid is not part of the agent. We postulate that Sp33-37, perhaps in concert with other unidentified host components, is capable of inducing the disease and directing the production of more of itself by acting on the normal protein directly or by affecting one of the steps in protein processing. Agent replication requires that: 1) a constant supply of the substrate protein Cp33-37 is available, 2) aggregates of Sp33-37 are resistant to degradation and accumulate in cells or cell membranes, and 3) membrane damage and cell death facilitate spread to adjacent cells. The model predicts that disease can be transmitted by the scrapie agent or initiated by a spontaneous metabolic error resulting in accumulation of the abnormal protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136999     DOI: 10.1002/9780470513613.ch11

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  12 in total

1.  Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy.

Authors:  J C Bartz; R A Bessen; D McKenzie; R F Marsh; J M Aiken
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Cellular biology of prion diseases.

Authors:  D A Harris
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

3.  Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy.

Authors:  R A Bessen; R F Marsh
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  An Amino Acid Substitution Found in Animals with Low Susceptibility to Prion Diseases Confers a Protective Dominant-Negative Effect in Prion-Infected Transgenic Mice.

Authors:  Alicia Otero; Rosa Bolea; Carlos Hedman; Natalia Fernández-Borges; Belén Marín; Óscar López-Pérez; Tomás Barrio; Hasier Eraña; Manuel A Sánchez-Martín; Marta Monzón; Juan José Badiola; Joaquín Castilla
Journal:  Mol Neurobiol       Date:  2017-12-20       Impact factor: 5.590

Review 5.  Prion protein interactions with nucleic acid: possible models for prion disease and prion function.

Authors:  Abraham Grossman; Brian Zeiler; Victor Sapirstein
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

6.  Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.

Authors:  Ronald A Shikiya; Thomas E Eckland; Alan J Young; Jason C Bartz
Journal:  Prion       Date:  2014       Impact factor: 3.931

Review 7.  Transgenic and knockout mice in the study of neurodegenerative diseases.

Authors:  A Aguzzi; S Brandner; S Marino; J P Steinbach
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

8.  Rapid, high-throughput detection of PrPSc by 96-well immunoassay.

Authors:  Michelle L Kramer; Jason C Bartz
Journal:  Prion       Date:  2009-01-13       Impact factor: 3.931

9.  Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent.

Authors:  R A Bessen; R F Marsh
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells.

Authors:  S A Priola; B Caughey; R E Race; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.